Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Usana Health Sciences (USNA) Other Non Operating Income (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Other Non Operating Income for 17 consecutive years, with -$14000.0 as the latest value for Q1 2026.

  • Quarterly Other Non Operating Income rose 96.41% to -$14000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Jan 2026, up 349.46% year-over-year, with the annual reading at $2.5 million for FY2026, 349.46% up from the prior year.
  • Other Non Operating Income for Q1 2026 was -$14000.0 at Usana Health Sciences, down from $41000.0 in the prior quarter.
  • The five-year high for Other Non Operating Income was $1.7 million in Q2 2025, with the low at -$1.2 million in Q1 2022.
  • Average Other Non Operating Income over 5 years is -$134117.6, with a median of -$186000.0 recorded in 2024.
  • The sharpest move saw Other Non Operating Income crashed 769.86% in 2022, then soared 598.28% in 2025.
  • Over 5 years, Other Non Operating Income stood at -$1.2 million in 2022, then skyrocketed by 68.71% to -$368000.0 in 2023, then decreased by 5.98% to -$390000.0 in 2024, then surged by 110.51% to $41000.0 in 2025, then plummeted by 134.15% to -$14000.0 in 2026.
  • According to Business Quant data, Other Non Operating Income over the past three periods came in at -$14000.0, $41000.0, and $1.7 million for Q1 2026, Q3 2025, and Q2 2025 respectively.